Xabier
Aguirre Ena
Profesional Investigador
![Foto de Xabier](/img/nophoto.png)
![Foto de Clínica Universitaria de Navarra](/img/noimage_org.png)
Clínica Universitaria de Navarra
Pamplona, EspañaPublicaciones en colaboración con investigadores/as de Clínica Universitaria de Navarra (19)
2013
-
Long non-coding RNAs in haematological malignancies
International Journal of Molecular Sciences, Vol. 14, Núm. 8, pp. 15386-15422
2012
-
Epigenetic regulation of miRNA genes in acute leukemia
Leukemia, Vol. 26, Núm. 3, pp. 395-403
2011
-
NPM1 gene deletions in myelodysplastic syndromes with 5q- and complex karyotype
Haematologica, Vol. 96, Núm. 5, pp. 784
2010
-
Epigenetic regulation of the non-canonical Wnt pathway in acute myeloid leukemia
Cancer Science, Vol. 101, Núm. 2, pp. 425-432
2009
-
Epigenetic down-regulation of BIM expression is associated with reduced optimal responses to imatinib treatment in chronic myeloid leukaemia
European Journal of Cancer, Vol. 45, Núm. 10, pp. 1877-1889
-
Epigenetic silencing of the tumor suppressor microRNA Hsa-miR-124a regulates CDK6 expression and confers a poor prognosis in acute lymphoblastic leukemia
Cancer Research, Vol. 69, Núm. 10, pp. 4443-4453
2008
-
BCR-ABL1-induced expression of HSPA8 promotes cell survival in chronic myeloid leukaemia
British Journal of Haematology, Vol. 142, Núm. 4, pp. 571-582
-
Down-regulation of hsa-miR-10a in chronic myeloid leukemia CD34+ cells increases USF2-mediated cell growth
Molecular Cancer Research, Vol. 6, Núm. 12, pp. 1830-1840
-
Mecanismos de resistencia primaria al tratamiento con imatinib
Medicina Clinica Monografias, Vol. 9, Núm. 8, pp. 3-7
-
Repetitive DNA hypomethylation in the advanced phase of chronic myeloid leukemia
Leukemia Research, Vol. 32, Núm. 3, pp. 487-490
2007
-
Epigenetic regulation of PRAME gene in chronic myeloid leukemia
Leukemia Research, Vol. 31, Núm. 11, pp. 1521-1528
-
WNT5A, a putative tumour suppressor of lymphoid malignancies, is inactivated by aberrant methylation in acute lymphoblastic leukaemia
European Journal of Cancer, Vol. 43, Núm. 18, pp. 2736-2746
2006
-
ASPP1, a common activator of TP53, is inactivated by aberrant methylation of its promoter in acute lymphoblastic leukemia
Oncogene, Vol. 25, Núm. 13, pp. 1862-1870
-
Abnormal methylation of the common PARK2 and PACRG promoter is associated with downregulation of gene expression in acute lymphoblastic leukemia and chronic myeloid leukemia
International Journal of Cancer, Vol. 118, Núm. 8, pp. 1945-1953
-
Downregulation of DBC1 expression in acute lymphoblastic leukaemia is mediated by aberrant methylation of its promoter
British Journal of Haematology, Vol. 134, Núm. 2, pp. 137-144
2005
-
Coexistence of different clonal populations harboring the b3a2 (p210) and e1a2 (p190) BCR-ABL1 fusion transcripts in chronic myelogenous leukemia resistant to imatinib
Cancer Genetics and Cytogenetics, Vol. 160, Núm. 1, pp. 22-26
-
Lack of CpG island methylator phenotype defines a clinical subtype of T-cell acute lymphoblastic leukemia associated with good prognosis
Journal of Clinical Oncology, Vol. 23, Núm. 28, pp. 7043-7049
2003
-
Lack of Bcr-Abl point mutations in chronic myeloid leukemia patients in chronic phase before imatinib treatment is not predictive of response
Haematologica, Vol. 88, Núm. 12, pp. 1425-1426